Pellino promotes lymphomagenesis by deregulating BCL polyubiquitination

Journal of Clinical Investigation

Volumn 124, Issue 11, 2014, Pages 4976-4988

  Park, Hye Young ^a   Go, Heounjeong ^b   Song, Ha Rim ^c   Kim, Suhyeon ^a   Ha, Geun Hyoung ^a   Jeon, Yoon Kyung ^d   Kim, Ji Eun ^d   Lee, Ho ^e   Cho, Hyeseong ^f   Kang, Ho Chul ^g   Chung, Hee Young ^h   Kim, Chul Woo ^d   Chung, Doo Hyun ^d   Lee, Chang Woo ^a,c  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e National Cancer Center   (South Korea)

^f Department of Biochemistry and Molecular Biology ^*  (South Korea)

^g Ajou University School of Medicine   (South Korea)

^h Hanyang University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD23 ANTIGEN; CD40 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN M ANTIBODY; INTERFERON REGULATORY FACTOR 4; INTERLEUKIN 10; INTERLEUKIN 6; KI 67 ANTIGEN; LIGAND; LYSINE; ONCOPROTEIN; PELLINO 1 PROTEIN; PREDNISONE; PROTEIN BCL 6; RITUXIMAB; T LYMPHOCYTE RECEPTOR; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; VINCRISTINE; BCL6 PROTEIN, HUMAN; DNA BINDING PROTEIN; NUCLEAR PROTEIN; PELI1 PROTEIN, HUMAN; POLYUBIQUITIN; UBIQUITIN PROTEIN LIGASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PROGNOSIS; CARCINOGENESIS; CD3+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE SEQUENCE; HELA CELL LINE; HELPER CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LIFESPAN; LYMPHATIC SYSTEM TUMOR; LYMPHOCYTIC INFILTRATION; LYMPHOMAGENESIS; MAJOR CLINICAL STUDY; MORTALITY; MOUSE; NONHUMAN; PATHOGENESIS; POLYUBIQUITINATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UBIQUITINATION; UPREGULATION; ANIMAL; C57BL MOUSE; KAPLAN MEIER METHOD; LYMPHANGIOGENESIS; METABOLISM; PHYSIOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN STABILITY; RECEIVER OPERATING CHARACTERISTIC; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; CARCINOGENESIS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHANGIOGENESIS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE, INBRED C57BL; MICE, TRANSGENIC; NUCLEAR PROTEINS; POLYUBIQUITIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN STABILITY; ROC CURVE; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84908632069     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI75667     Document Type: Article

References (29)

1. Schauvliege R, Janssens S, Beyaert R. Pellino proteins: Novel players in TLR and IL-1R signalling. J Cell Mol Med. 2007;11(3):453-461.
2. Chang M, Jin W, Sun SC. Peli1 facilitates TRIFdependent Toll-like receptor signaling and proinflammatory cytokine production. Nat Immunol. 2009;10(10):1089-1095.
3. Conze DB, Wu CJ, Thomas JA, Landstrom A, Ashwell JD. Lys63-linked polyubiquitination of IRAK-1 is required for interleukin-1 receptor- And toll-like receptor-mediated NF-κB activation. Mol Cell Biol. 2008;28(10):3538-3547.
4. Moynagh PN. The Pellino family: IRAK E3 ligases with emerging roles in innate immune signalling. Trends Immunol. 2009;30(1):33-42.
5. Schauvliege R, Janssens S, Beyaert R. Pellino proteins are more than scaffold proteins in TLR/IL-1R signalling: A role as novel RING E3-ubiquitin- ligases. FEBS Lett. 2006;580(19):4697-4702.
6. Chang M, et al. The ubiquitin ligase Peli1 negatively regulates T cell activation and prevents autoimmunity. Nat Immunol. 2011;12(10):1002-1009.
7. Siednienko J, et al. Pellino3 targets the IRF7 pathway and facilitates autoregulation of TLR3- And viral-induced expression of type I interferons. Nat Immunol. 2012;13(11):1055-1062.
8. Moynagh PN. Peli1 (rel)ieves autoimmunity. Nat Immunol. 2011;12(10):927-929.
9. Smith H, et al. The role of TBK1 and IKKepsilon in the expression and activation of Pellino 1. Biochem J. 2011;434(3):537-548.
10. Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G. Toll-like receptors: Lessons to learn from normal and malignant human B cells. Blood. 2008;112(6):2205-2213.
11. Shaffer AL 3rd, Young RM, Staudt LM. Pathogenesis of human B cell lymphomas. Annu Rev Immunol. 2012;30:565-610.
12. Basso K, Dalla-Favera R. BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis. Adv Immunol. 2010;105:193-210.
13. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregulation in B-cell lymphomas. Blood. 2003;101(4):1220-1235.
14. Bastard C, et al. LAZ3 rearrangements in non- Hodgkin's lymphoma: Correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood. 1994;83(9):2423-2427.
15. Offit K, et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med. 1994;331(2):74-80.
16. Pasqualucci L, et al. Molecular pathogenesis of non-Hodgkin's lymphoma: The role of Bcl-6. Leuk Lymphoma. 2003;44(suppl 3):S5-S12.
17. Duan S, et al. FBXO11 targets BCL6 for degradation and is inactivated in diffuse large B-cell lymphomas. Nature. 2012;481(7379):90-93.
18. Gerondakis S, Grumont RJ, Banerjee A. Regulating B-cell activation and survival in response to TLR signals. Immunol Cell Biol. 2007;85(6):471-475.
19. Pasare C, Medzhitov R. Control of B-cell responses by Toll-like receptors. Nature. 2005;438(7066):364-368.
20. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med. 1988;167(2):353-371.
21. Coutinho R, et al. Poor concordance among nine immunohistochemistry classifiers of cell-oforigin for diffuse large B-cell lymphoma: implications for therapeutic strategies. Clin Cancer Res. 2013;19(24):6686-6695.
22. Park YH, et al. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Ann Hematol. 2006;85(4):257-262.
23. Chau V, et al. A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein. Science. 1989;243(4898):1576-1583.
24. Hofmann RM, Pickart CM. Noncanonical MMS2- encoded ubiquitin-conjugating enzyme functions in assembly of novel polyubiquitin chains for DNA repair. Cell. 1999;96(5):645-653.
25. Butler MP, Hanly JA, Moynagh PN. Kinase-active interleukin-1 receptor-associated kinases promote polyubiquitination and degradation of the Pellino family: direct evidence for PELLINO proteins being ubiquitin-protein isopeptide ligases. J Biol Chem. 2007;282(41):29729-29737.
26. Browne EP. Regulation of B-cell responses by Toll-like receptors. Immunology. 2012;136(4):370-379.
27. Davis RE, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88-92.
28. Crotty S, Johnston RJ, Schoenberger SP. Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat Immunol. 2010;11(2):114-120.
29. Iqbal J, et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia. 2007;21(11):2332-2343.